The FDA has granted priority review to satralizumab, also known as Enspryng, for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD. This rare autoimmune disorder affects the central nervous system and currently has no approved treatments. If the agency approves the drug, it would stand as the first disease-modifying therapy for the condition. An FDA decision is expected by January 10, 2027.
MOGAD is estimated to affect between 0.51 and 3.42 per 100,000 people. The condition causes relapsing attacks on the optic nerves, brain, and spinal cord. These attacks can lead to vision loss, weakness, and accumulating disability. Because no specific treatments exist, doctors have had to rely on off-label immunosuppressive therapies. They often use high-dose steroids to manage acute relapses. This approach is based on extrapolation from related conditions rather than direct trial evidence.
Key Data from the METEOROID Trial
The supplemental biologics license application rests on results from the phase 3 METEOROID study. This randomized, double-blind, placebo-controlled trial enrolled adults and adolescents aged 12 and older with relapsing MOGAD. The study concluded after 28 adjudicated relapses occurred across the population. Findings were presented at the 2026 American Academy of Neurology Annual Meeting.
In the trial, satralizumab reduced the risk of a first adjudicated relapse by 68% compared with placebo. The treatment effect emerged as early as week 8. At 48 weeks, 87% of patients on satralizumab remained relapse-free, compared with 67% of those on placebo. The annualized relapse rate dropped by 66%. Active MRI lesion activity across the optic nerves, brain, and spinal cord decreased by 79% in the annualized rate.
Read Also: Gene therapy shows promise for seizure patients
Patients receiving satralizumab also required less rescue therapy. The proportion needing steroids, plasma exchange, or intravenous immunoglobulin was 73% lower. Inpatient hospitalizations were numerically reduced by 17%, though this specific difference did not reach statistical significance. The treatment benefit was consistent across subgroups defined by age, sex, race, and background immunosuppressive therapy use.
Current Management and Therapeutic Gaps
Without an approved therapy, MOGAD management has traditionally mirrored other relapsing CNS autoimmune diseases. Acute attacks are typically treated with high-dose intravenous corticosteroids. If patients do not respond fully, clinicians often follow up with plasma exchange or intravenous immunoglobulin. For relapse prevention, doctors rely on off-label maintenance immunosuppression. Common agents include rituximab, azathioprine, mycophenolate mofetil, or long-term intravenous immunoglobulin. None of these carry an indication specific to MOGAD.
The current standard of care relies heavily on observational data. Clinicians use these tools based on extrapolation from related conditions.
If approved, satralizumab would address a critical gap in neurological care. The drug has a long history in treating neuromyelitis optica spectrum disorder. That experience provides a foundation for its safety profile in MOGAD.
Read Also: How America fights back against populism
Safety Profile and Regulatory Pathway
The safety profile of satralizumab in METEOROID was consistent with over 10 years of data. This includes clinical trials and postmarketing experience in neuromyelitis optica spectrum disorder. More than 10,000 patients have been treated with the drug in that context. Adverse events occurring in 5% or more of satralizumab-treated patients included injection-related reactions at 16%. Other events included influenza and arthralgia at 9%, back pain at 9%, sinusitis at 7%, and diarrhea at 6%. Treatment interruptions occurred in 6% of patients on the drug versus 5% on placebo.
One death occurred during the study but was assessed as unrelated to treatment. No serious adverse events were attributed to satralizumab. The European Medicines Agency has separately validated a corresponding application. A European Commission decision is anticipated in the third quarter of 2027.
Levi Garraway, MD, PhD, Roche’s chief medical officer, stated that MOGAD can be unpredictable and debilitating. He noted that each relapse carries the potential for lasting neurological damage. “Enspryng has the potential to transform care for people living with MOGAD, significantly reducing serious attacks and decreasing the reliance on high-dose steroids and immunosuppressants,” Garraway said. Michael Levy, MD, PhD, associate professor at Harvard Medical School and Massachusetts General Hospital, said in a presentation of the METEOROID data, “This would be the first proven therapy, scientifically proven, hopefully FDA approved, that would essentially prevent relapses in our MOGAD population.”